Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer

This study has been completed.
Brigham and Women's Hospital
Massachusetts General Hospital
Information provided by (Responsible Party):
Craig A. Bunnell, MD, MPH, Dana-Farber Cancer Institute Identifier:
First received: September 8, 2005
Last updated: February 5, 2013
Last verified: February 2013

The purpose of this study is to find the highest dose of capecitabine and oral navelbine that can be given without causing severe side effects, and to determine the safety, tolerability, and effects (good and bad) of capecitabine given with oral navelbine to patients with advanced breast cancer.

Condition Intervention Phase
Breast Cancer
Drug: Navelbine
Drug: Capecitabine
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Study of Oral Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer

Resource links provided by NLM:

Further study details as provided by Dana-Farber Cancer Institute:

Primary Outcome Measures:
  • To define the maximally tolerated dose and evaluate the feasibility and toxicity of capecitabine and oral navelbine administered in combination. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]

Enrollment: 40
Study Start Date: March 2002
Study Completion Date: September 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Navelbine
    Given orally on day 1 and 8 of each cycle, dose will vary. If participant is at highest dose they will take navelbine on day 1, 8 and 15 until disease progression or unacceptable side effects occur.
    Drug: Capecitabine
    Taken twice a day on days 1-14 until disease progression or unacceptable side effects occur.
    Other Name: Xeloda
Detailed Description:
  • Not every patient will be receiving the same dose of capecitabine and navelbine. A small group will be enrolled onto the study and given certain doses of each drug. If they tolerate them well (have few or easily manageable side effects), the next small group of people enrolled will receive a higher dose of one of the drugs. This will continue until we find the highest doses of the drugs that can be given without causing serious or unmanageable side effects.
  • Patients will be given oral navelbine on days 1 and 8 of each cycle, unless they are at the highest dose. In which case, they will be given navelbine on days 1, 8 and 15. Capecitabine will be given on days 1-14 of each cycle in two divided doses approximately 12 hours apart.
  • While patients are on the study they will have the following tests and procedures performed: physical examination every 3 weeks; routine blood work every week; extensive laboratory tests every 3 weeks; disease status will be checked every 6 weeks (2 cycles) unless there are symptoms of disease progression.
  • The weekly treatment will continue unless there is disease progression or unacceptable side effects.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed breast cancer with evidence of locally advanced or metastatic disease
  • Female patients age 18 or older
  • No more than three prior chemotherapeutic regimens in the metastatic setting
  • ANC > 1,500/mm3
  • Platelet count > 100,000/mm3
  • SGOT < 3 x ULN
  • Bilirubin < 1.5 x ULN
  • Performance status of 0 or 1
  • At least 3 weeks since prior chemotherapy or 2 weeks since prior radiation, surgery or any anticancer investigational agent
  • Able to swallow and retain oral medications
  • Measurable disease

Exclusion Criteria:

  • Prior vinca alkaloids
  • Active gastrointestinal disease or disorder
  • Pregnant or lactating
  • Serious co-morbid medical or psychological condition
  • Prior bone marrow or stem cell transplant
  • Prior documented severe sensitivity to 5-FU
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00153907

United States, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Massachusetts General Hospital
Principal Investigator: Craig A. Bunnell, MD Dana-Farber Cancer Institute
  More Information

No publications provided

Responsible Party: Craig A. Bunnell, MD, MPH, Principal Investigator, Dana-Farber Cancer Institute Identifier: NCT00153907     History of Changes
Other Study ID Numbers: 01-217
Study First Received: September 8, 2005
Last Updated: February 5, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Dana-Farber Cancer Institute:
metastatic breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms by Site
Skin Diseases
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 20, 2014